APOA1 and metabolic syndrome: In diabetic or dyslipidemic populations, novel variants (e.g., rs2066714 and rs757194699) are linked to increased susceptibility to dyslipidemia through altered ABCA1-apoA1 interaction and impaired lipid efflux capacity [20].